COQ10 AND GPI 1485 IN SUBJECTS WITH EARLY UNTREATED PARKINSON'S

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。帕金森病(PD)是最常见的成人起病神经退行性疾病之一，在北美约有100万人受到影响。帕金森病会导致震颤、运动、平衡和思维随着时间的推移而进展的问题。这是对两种可能减缓帕金森氏病(PD)进展的药物的初步研究：辅酶Q10和GPI 1485。辅酶Q10(CoQ)是一种抗氧化剂，可以减缓对帕金森氏症重要细胞的损害。GPI 1485(GPI)是一种可能导致大脑神经生长的物质。这项研究将在42个地点进行，将招募195名年龄在30岁或以上的早期未经治疗的帕金森病患者。受试者将被随机分配到辅酶Q、GPI或安慰剂。随机意味着偶然，就像抛硬币一样。安慰剂是指一种看起来像辅酶Q或GPI的非活性物质，但预计不会对帕金森病产生任何影响。受试者将接受为期12个月的监测，并将跟踪他们的疾病进展。在此期间，受试者将完成一次筛查访问和6次监测访问。要检查的主要结果是被称为统一帕金森病评定量表(UPDRS)的评级表的变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Parkinson's disease (PD) is one of the most common adult-onset neurodegenerative disorders, affecting approximately 1 million people in North America. PD can cause problems with tremors, movement, balance, and thinking that progress over time. This is a pilot study of 2 agents that may slow the progression of Parkinson's Disease (PD): CoEnzyme Q10 and GPI 1485. CoEnzyme Q10 (CoQ) is an antioxidant that may slow damage to cells important in Parkinson's disease. GPI 1485 (GPI) is a substance that may cause nerve growth in the brain. This study will occur at 42 sites and will enroll 195 subjects with early, untreated PD, ages 30 or older. Subjects will be randomly assined to CoQ, GPI, or placebo. Randomly means by chance, like flipping a coin. Placebo means an inactive substance that looks like CoQ or GPI, but is not expected to have any effect on PD. Subjects will be monitored for 12 months, and their disease progression will be tracked. During this time, subjects will complete a screening visit and 6 monitoring visits. The main outcome to be examined is the change in a rating scale known as the Unified Parkinson Disease Rating Scale (UPDRS).